A Study to Evaluate the Renal Protective Effect (Urine Albumin-to-Creatinine Ratio (UACR)), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus Patients With Albuminuria

NCT03118713 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

33

Enrollment

INDUSTRY

Sponsor class

Stopped Business decision due to enrollment challenges

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: metformin
DRUG: ipragliflozin
DRUG: glimepiride

Sponsor

Astellas Pharma Korea, Inc.